Pharm5

Pharm5

By Elizabeth B. Hearn, PharmD, BCACPMedicineHealth & Fitness
Download on the App Store

Pharm5 episodes

  • Pneumonia vaccine guidance, pharmacist billing codes, and more!

    This week on Pharm5:

    • Novavax protein-based COVID-19 vaccine
    • Pneumococcal Vaccine Decision Tree
    • Dupixent (dupilumab) for atopic dermatitis in kids 6 months to 5 years
    • Dostarlimab 100% effective in Phase II colorectal cancer trial
    • CHIP and Medicaid COVID-19 vaccine counseling codes


      • References:

      1. FDA Briefing Document Novavax COVID-19 Vaccine. FDA.gov. https://bit.ly/3tsOBxb. Published June 7, 2022. Accessed June 9, 2022.
      2. Haslett C, Carrington AE. ABC News. https://abcn.ws/3O2JtI3. Published June 7, 2022. Accessed June 9, 2022.
      3. Protecting adults against pneumococcal disease. National Foundation for Infectious Diseases. https://bit.ly/3aKYXlz. Published June 3, 2022. Accessed June 9, 2022.
      4. Brunk D. Dupilumab approved for eczema for children 6 months to 5 years. Medscape. https://wb.md/3QoWAFF. Published June 7, 2022. Accessed June 9, 2022.
      5. Cercek A, Lumish M, Sinopoli J, et al. PD-1 blockade in mismatch repair–deficient, locally advanced rectal cancer. New England Journal of Medicine. 2022. doi:10.1056/nejmoa2201445
      6. COVID-19 Stand-alone Vaccine Counseling-specific HCPCS Codes. Federal Policy Guidance | Medicaid.gov. https://bit.ly/3QffkY0. Published June 8, 2022. Accessed June 9, 2022.
        7. 5 min
      7. Monkeypox vaccine, Ukoniq loses FDA approval, and more!

        This week on Pharm5:

        • Monkeypox vaccine for work-related exposure to orthopoxvirus
        • Lymphoma drug Ukoniq (umbralisib) loses FDA approval
        • Psychedelic, synthetic psylocibin tested for use in severe depression
        • Expanding uses for antineoplastic agent azacitidine
        • Addendum to the 2022 Standards of Medical Care in Diabetes


          • References:

          1. Use of JYNNEOS (smallpox and monkeypox vaccine, live, nonreplicating) for preexposure vaccination of persons at risk for occupational exposure to orthopoxviruses: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022. Centers for Disease Control and Prevention. https://bit.ly/3MkpYtq. Published May 27, 2022. Accessed June 2, 2022.
          2. FDA withdraws lymphoma drug approval after investigation. Medscape. https://wb.md/3GJIMRw. Published June 1, 2022. Accessed June 2, 2022.
          3. Melville NA. Psilocybin effective up to 12 weeks in severe depression. Medscape. https://wb.md/3xeigg5. Published June 2, 2022. Accessed June 2, 2022.
          4. DRUGS@FDA: FDA-approved drugs. accessdata.fda.gov. https://bit.ly/3Mr6kvT. Accessed June 2, 2022.
          5. Center for Drug Evaluation and Research. FDA approves azacitidine. U.S. Food and Drug Administration. https://bit.ly/3xdSoRw. Published May 20, 2022. Accessed June 2, 2022.
          6. FDA approves Ivosidenib/Azacitidine for certain patients with newly diagnosed AML. The ASCO Post. https://bit.ly/3GHaoGY. Published May 26, 2022. Accessed June 2, 2022.
          7. Addendum. 10. cardiovascular disease and risk management: Standards of medical care in diabetes–2022. diabetes care 2022;45(suppl. 1):S144–S174. Diabetes Care. May 2022. doi:10.2337/dc22-ad08
          8. Aspirin use to prevent cardiovascular disease: Preventive medication. Recommendation: Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication | United States Preventive Services Taskforce. https://bit.ly/3m93gtn. Published April 26, 2022. Accessed Jun 2, 2022.
            9. 5 min
          9. Monkeypox, metformin for breast cancer, money saved from vaccines, and more!

            This week on Pharm5:

            • Rare monkeypox spreading globally
            • Metformin not helpful in breast cancer survival
            • Novel, nonsteroidal Vtama (tapinarof) for plaque psoriasis
            • Short-course antibiotics for P. aeruginosa bacteremia
            • COVID-19 vaccine saves lives and money


              • References:

              1. LaMotte S. What is monkeypox, its symptoms and threat to you? CNN. https://www.cnn.com/2022/05/24/health/what-is-monkeypox-virus-explainer-update-wellness/index.html. Published May 26, 2022. Accessed May 26, 2022.
              2. Goodwin PJ, Chen BE, Gelmon KA, et al. Effect of Metformin vs Placebo on Invasive Disease–Free Survival in Patients with Breast Cancer. Journal of the American Medical Association. 2022;327(20):1963-1973. doi:10.1001/jama.2022.6147.
              3. Kansteiner F. Dermavant looks to dethrone topical steroids with first FDA approval for Vtama in psoriasis. Fierce Pharma. https://www.fiercepharma.com/pharma/dermavant-looks-dethrone-topical-steroids-first-ever-fda-approval-vtama-psoriasis. Published May 24, 2022. Accessed May 26, 2022.
              4. Dermavant Sciences. Dermavant FDA Approves Dermavants VTAMA tapinarof cream 1 for the Treatment of Plaque Psoriasis in Adults First Topical Novel Chemical Entity Launched for Psoriasis in the US in 25 Years Comments. https://www.dermavant.com/u-s-fda-approves-our-novel-topical-treatment-for-adults-with-plaque-psoriasis/. Accessed May 26, 2022.
              5. Babich T, Naucler P, Valik JK, et al. Duration of treatment for pseudomonas aeruginosa bacteremia: A retrospective study. Infectious Diseases and Therapy. 2022. doi:10.1007/s40121-022-00657-1
              6. Di Fusco M, Marczell K, Deger KA, et al. Public health impact of the pfizer-biontech COVID-19 vaccine (BNT162B2) in the first year of rollout in the United States. Journal of Medical Economics. 2022;25(1):605-617. doi:10.1080/13696998.2022.2071427.
                7. 4 min
              7. May 20, 2022

                This week on Pharm5:

                • IV contrast shortage
                • COVID-19 boosters for kids 5-11 years old
                • First-in-class tirzepatide for T2DM
                • Oral Radacava ORS for ALS
                • COVID-19 vaccines in AAPI patients


                  • References:

                  1. Shortage of contrast dye forces hospitals to ration CT scans, other procedures. NBCNews.com. https://www.nbcnews.com/news/us-news/shortage-contrast-dye-hospitals-ration-ct-scans-procedures-rcna29379. Published May 18, 2022. Accessed May 19, 2022.
                  2. Commissioner Oof the. Coronavirus (COVID-19) update: FDA expands eligibility for Pfizer BioNTech COVID-19 vaccine booster dose to children 5 through 11 years. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-expands-eligibility-pfizer-biontech-covid-19-vaccine-booster-dose. Published May 17, 2022. Accessed May 19, 2022.
                  3. Children and covid-19 vaccination trends. Home. https://www.aap.org/en/pages/2019-novel-coronavirus-covid-19-infections/children-and-covid-19-vaccination-trends/. Accessed May 19, 2022.
                  4. Commissioner of the FDA approves novel, dual-targeted treatment for type 2 diabetes. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-approves-novel-dual-targeted-treatment-type-2-diabetes. Published May 13, 2022. Accessed May 19, 2022.
                  5. Radicava ORS (Edaravone) Patient Brochure. https://www.radicava.com/update/pdfs/radicava-ors-patient-brochure.pdf. Accessed May 19, 2022.
                  6. Galvez-Jiminez N, Goyal NA, Cudkowicz ME. Disease-modifying treatment of amyotrophic lateral sclerosis. UpToDate. http://www.utdol.com. Updated May 17, 2022. Accessed May 19, 2022.
                  7. Dahl D, Onishi Y, Norwood P, et al. Effect of subcutaneous Tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes. JAMA. 2022;327(6):534. doi:10.1001/jama.2022.0078
                  8. Bureau USC. Week 45 household pulse survey: April 27 - May 9, 2022. Census.gov. https://www.census.gov/data/tables/2022/demo/hhp/hhp45.html. Published May 18, 2022. Accessed May 19, 2022.
                  9. Ta Park V, Dougan M, Meyer O, et al. Differences in covid-19 vaccine concerns among Asian Americans and Pacific Islanders: The compass survey. Journal of Racial and Ethnic Health Disparities. 2021;9(3):979-991. doi:10.1007/s40615-021-01037-0
                    10. 4 min
                  10. May 13, 2022

                    This week on Pharm5:

                    • Adenovirus 41 infections in kids <5 years old
                    • Mediterranean diet superior to low-fat diet for CVD prevention in males
                    • Of hospitalized COVID-19 patients, over half still experience ≥1 symptom after 2 years
                    • Overdose deaths hit record high in 2021
                    • Former nurse RaDonda Vaught’s sentencing expected today


                      • References:

                      1. Rosenthal M. Idse.net. https://www.idse.net/Emerging-Diseases/Article/05-22/Pediatric-Hepatitis-of-Unknown-Origin-Cases-Mounting/66928. Accessed May 12, 2022.
                      2. Overview: Children with hepatitis of unknown cause. Centers for Disease Control and Prevention. https://www.cdc.gov/ncird/investigation/hepatitis-unknown-cause/overview-what-to-know.html. Published May 6, 2022. Accessed May 12, 2022.
                      3. Adenovirus vaccine information statement. Centers for Disease Control and Prevention. https://www.cdc.gov/vaccines/hcp/vis/vis-statements/adenovirus.html. Published January 8, 2020. Accessed May 12, 2022.
                      4. Delgado-Lista J, Alcala-Diaz JF, Torres-Peña JD, et al. Long-term secondary prevention of cardiovascular disease with a Mediterranean diet and a low-fat diet (CORDIOPREV): A randomised controlled trial. The Lancet. 2022. doi:10.1016/s0140-6736(22)00122-2
                      5. Huang L, Li X, Gu X, et al. Health Outcomes in people 2 years after surviving hospitalisation with covid-19: A longitudinal cohort study. The Lancet Respiratory Medicine. 2022. doi:10.1016/s2213-2600(22)00126-6
                      6. Naloxone: The opioid reversal drug that saves lives - hhs.gov. https://www.hhs.gov/opioids/sites/default/files/2018-12/naloxone-coprescribing-guidance.pdf. Accessed May 12, 2022.
                      7. Shaw G. Vaught Verdict a ‘Blow’ To Patient Safety Culture. Pharmacypracticenews.com. https://www.pharmacypracticenews.com/Operations-and-Management/Article/05-22/Vaught-Verdict-a-%E2%80%98Blow%E2%80%99-To-Patient-Safety-Culture/66894. Accessed May 12, 2022.
                        8. 4 min
                      8. May 6, 2022

                        This week on Pharm5:

                        • AAPI patients underrepresented in clinical trials
                        • Camzyos (mavacamten) approved for obstructive HCM
                        • Voquenza (combination vonoprazan products) approved for H. pylori
                        • Pharmacy job postings up 18% in 2021
                        • Implications of potential overturn of Roe v. Wade


                          • References:

                          1. Asian, Indigenous, Latino patients underrepresented in US clinical trials of Biologics. Healio. https://www.healio.com/news/rheumatology/20211208/asian-indigenous-latino-patients-underrepresented-in-us-clinical-trials-of-biologics#:~:text=Asian%2C%20American%20Indian%2C%20Alaska%20Native,research%20letter%20published%20in%20JAMA. Accessed May 5, 2022.
                          2. Camzyos Prescribing Information. accessdata.fda.gov. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=214998. Accessed May 5, 2022.
                          3. Cosdon N. FDA approves 2 vonoprazan treatments for helicobacter pylori infection. Contagion Live. https://www.contagionlive.com/view/fda-approves-2-vonoprazan-treatments-for-helicobacter-pylori-infection. Published May 3, 2022. Accessed May 5, 2022.
                          4. Staff PT. FDA approves pair of Vonoprazan treatments for helicobacter pylori infection. Pharmacy Times. https://www.pharmacytimes.com/view/fda-approves-pair-of-vonoprazan-treatments-for-helicobacter-pylori-infection. Published May 4, 2022. Accessed May 5, 2022.
                          5. Pharmacy Demand Report (PDR) 2021 Yearly Summary - aacp.org. https://www.aacp.org/sites/default/files/2022-04/pdr-2021-yearly-summary.pdf. Accessed May 5, 2022.
                          6. Roe v. Wade live updates: Protests rage on over leaked abortion ruling. NBCNews.com. https://www.nbcnews.com/news/us-news/live-blog/roe-v-wade-live-updates-protests-rage-leaked-abortion-ruling-rcna27427. Published May 5, 2022. Accessed May 5, 2022.
                            7. 4 min
                          7. April 29, 2022

                            This week on Pharm5:

                            • Vivjoa to prevent recurrent vulvovaginal candidiasis
                            • USPSTF recommendations for aspirin in primary prevention
                            • Remdesivir FDA approved in kids ≤12 years old
                            • Moderna applies for EAU in kids 6 months to 5 years old
                            • National Prescription Drug Take Back Day tomorrow, April 30th


                              • Connect with us!

                              • Listen to our podcast: Pharm5
                              • Watch us on TikTok: @LizHearnPharmD
                              • Follow us on Twitter: @LizHearnPharmD


                                • References:

                                1. Vivjoa. Package Insert. Mycovia Pharmaceuticals, Inc.; 2022.
                                2. FDA approves Mycovia Pharmaceuticals' VIVJOA™ (oteseconazole), the first and only FDA-approved medication for recurrent vulvovaginal candidiasis (chronic yeast infection). BioSpace. https://www.biospace.com/article/releases/fda-approves-mycovia-pharmaceuticals-vivjoa-oteseconazole-the-first-and-only-fda-approved-medication-for-recurrent-vulvovaginal-candidiasis-chronic-yeast-infection-/. Published April 28, 2022. Accessed April 28, 2022.
                                3. Aspirin use to prevent cardiovascular disease: Preventive medication. Recommendation: Aspirin Use to Prevent Cardiovascular Disease: Preventive Medication | United States Preventive Services Taskforce. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation/aspirin-to-prevent-cardiovascular-disease-preventive-medication. Published April 26, 2022. Accessed April 28, 2022.
                                4. Gumbrecht J, Howard J. FDA approves remdesivir to treat young children with covid-19. CNN. https://www.cnn.com/2022/04/25/health/fda-remdesivir-covid-treatment-young-children/index.html.  Published April 25, 2022. Accessed April 28, 2022.
                                5. Hur K. Pfizer director dr. Scott Gottlieb: Shots for kids under 5 delayed due to low Covid cases in trial. CNBC. https://www.cnbc.com/2022/02/14/pfizer-director-dr-scott-gottlieb-shots-for-kids-under-5-delayed-due-to-low-covid-cases-in-trial.html. Published February 14, 2022. Accessed April 28, 2022.
                                6. Goodman B. Moderna seeks emergency use authorization for covid-19 vaccine for children ages 6 months through 5 years. CNN. https://www.cnn.com/2022/04/28/health/moderna-vaccine-eua-young-children/index.html?utm_term=link&utm_content=2022-04-28T13%3A49%3A07&utm_source=twCNN&utm_medium=social. Published April 28, 2022. Accessed April 28, 2022.
                                7. Take back day. DEA. https://www.dea.gov/takebackday. Accessed April 28, 2022.
                                  8. 4 min
                                8. April 22, 2022

                                  This week on Pharm5:

                                  • Oral tebipenem noninferior to IV ertapenem for complicated UTIs
                                  • Stelara’s potential biosimilar ustekinumab ABP 654’s promising results
                                  • SODIUM-HF trial finds no benefit to extreme sodium restriction in heart failure
                                  • InspectIR COVID-19 Breathalyzer receives EUA
                                  • Avastin’s third biosimilar bevacizumab-maly (Almsys) approved


                                    • Connect with us!

                                    • Listen to our podcast: Pharm5
                                    • Watch us on TikTok: @LizHearnPharmD
                                    • Follow us on Twitter: @LizHearnPharmD


                                      • References:

                                      1. Eckburg PB, Muir L, Critchley IA, et al. Oral tebipenem pivoxil hydrobromide in complicated urinary tract infection. New England Journal of Medicine. 2022;386(14):1327-1338. doi:10.1056/nejmoa2105462.
                                      2. Amgen announces positive top-line results from phase 3 study of ABP 654, Biosimilar candidate to STELARA® (ustekinumab). Amgen. https://www.amgen.com/newsroom/press-releases/2022/04/amgen-announces-positive-topline-results-from-phase-3-study-of-abp-654-biosimilar-candidate-to-stelara-ustekinumab. Published April 18, 2022. Accessed April 20, 2022.
                                      3. Jeremias S. Amgen releases Positive Phase 3 results for Stelara Biosimilar. The Center For Biosimilars. https://www.centerforbiosimilars.com/view/amgen-releases-positive-phase-3-results-for-stelara-biosimilar. Published April 19, 2022. Accessed April 20, 2022.
                                      4. Ezekowitz JA, Colin-Ramirez E, Ross H, et al. Reduction of dietary sodium to less than 100 mmol in heart failure (Sodium-Hf): An international, open-label, randomised, controlled trial. The Lancet. 2022;399(10333):1391-1400. doi:10.1016/s0140-6736(22)00369-5.
                                      5. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. Journal of the American College of Cardiology. April 2022. doi:10.1016/j.jacc.2021.12.012
                                      6. Commissioner of the Coronavirus (COVID-19) update: FDA authorizes first COVID-19 diagnostic test using breath samples. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-covid-19-diagnostic-test-using-breath-samples. Published April 14, 2022. Accessed April 20, 2022.
                                      7. Pharmacypracticenews.com. https://www.pharmacypracticenews.com/FDA-Approvals/Article/05-22/Third-Biosimilar-to-Bevacizumab-Approved/66766. Published April 19, 2022. Accessed April 21, 2022.
                                        8. 4 min
                                      8. April 15, 2022

                                        This week on Pharm5:

                                        • FDA and DEA warn of online CII sales
                                        • Ultomiris (ravulizumab) improves ADLs and QOL for up to 60 weeks in patients with myasthenia gravis
                                        • Fidaxomicin’s biomolecular specificity to C. diffunveiled
                                        • Sotrovimab has lost its EUA for treatment of COVID-19
                                        • Results from Phase II of ASHP’s Residency Match


                                          • Connect with us!

                                          • Listen to our podcast: Pharm5
                                          • Watch us on TikTok: @LizHearnPharmD
                                          • Follow us on Twitter: @LizHearnPharmD


                                            • References:

                                            1. McCarthy L-J. FDA and DEA warn online pharmacies illegally selling Adderall to consumers. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-and-dea-warn-online-pharmacies-illegally-selling-adderall-consumers. Published April 12, 2022. Accessed April 12, 2022.
                                            2. Ultomiris® (ravulizumab-CWVZ) demonstrated sustained improvements in functional activities and quality of life in adults with generalized myasthenia gravis through 60 weeks. AstraZeneca US. https://www.astrazeneca-us.com/media/press-releases/2022/ultomiris-demonstrated-sustained-improvements-in-functional-activities-and-quality-of-life-in-adults-with-generalized-myasthenia-gravis-through-60-weeks.html. Published April 6, 2022. Accessed April 14, 2022.
                                            3. Ultomiris (ravulizumab-CWVZ). Package insert. Alexion Pharmaceuticals, Inc; 2018.
                                            4. Cao X, Boyaci H, Chen J, Bao Y, Landick R, Campbell EA. Basis of narrow-spectrum activity of fidaxomicin on Clostridioides difficile. Nature. April 2022. doi:10.1038/s41586-022-04545-z
                                            5. Rockefeller University. How a narrow-spectrum antibiotic takes aim at C. Diff. EurekAlert! https://www.eurekalert.org/news-releases/948950. Published April 6, 2022. Accessed April 14, 2022.
                                            6. Center for Drug Evaluation and Research. FDA updates Sotrovimab Emergency Use Authorization. U.S. Food and Drug Administration. https://www.fda.gov/drugs/drug-safety-and-availability/fda-updates-sotrovimab-emergency-use-authorization. Published April 5, 2022. Accessed April 14, 2022.
                                            7. Person, Kavya B AM. Worldwide covid cases surpass 500 mln as Omicron variant BA.2 surges. Reuters. https://www.reuters.com/business/healthcare-pharmaceuticals/worldwide-covid-cases-surpass-500-mln-omicron-variant-ba2-surges-2022-04-14/. Published April 14, 2022. Accessed April 14, 2022.
                                            8. Schedule of dates. ASHP Match | Schedule. https://natmatch.com/ashprmp/schedule.html. Published April 13, 2022. Accessed April 14, 2022.
                                            9. ASHP Match Statistics. ASHP Match | Statistics of the Match. https://natmatch.com/ashprmp/stats.html.  Published April 13, 2022. Accessed April 14, 2022.
                                              10. 5 min
                                            10. April 8, 2022

                                              This week on Pharm5:

                                              What most pharmacists need to know about the 2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure!


                                              Connect with us!

                                              • Listen to our podcast: Pharm5
                                              • Watch us on TikTok: @LizHearnPharmD
                                              • Follow us on Twitter: @LizHearnPharmD


                                                • References:

                                                1. Heidenreich PA, Bozkurt B, Aguilar D, et al. 2022 AHA/ACC/HFSA guideline for the management of heart failure. Journal of the American College of Cardiology. April 2022. doi:10.1016/j.jacc.2021.12.012
                                                2. Colvin MM. 2022 AHA/ACC/HFSA Heart Failure Guideline: Key Perspectives. American College of Cardiology. https://www.acc.org/Latest-in-Cardiology/ten-points-to-remember/2022/03/29/19/53/2022-AHA-ACC-HFSA-Heart-Failure-Guideline-gl-hf. Published April 1, 2022. Accessed April 7, 2022.
                                                3. Guideline hub: Heart failure. American College of Cardiology. https://www.acc.org/guidelines/hubs/heart-failure?utm_medium=social&utm_source=twitter_post&utm_campaign=twitter_post. Published April 1, 2022. Accessed April 7, 2022.
                                                  4. 5 min

                                                About Pharm5

                                                From the publisher's feed

                                                The top five things happening in pharmacy this week in five minutes or less! Hosted by assistant professor of pharmacotherapy and board certified ambulatory care pharmacist, Dr. Elizabeth B. Hearn.